Compare BLMN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLMN | DRTS |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.3M | 641.6M |
| IPO Year | 2012 | N/A |
| Metric | BLMN | DRTS |
|---|---|---|
| Price | $8.51 | $10.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $7.88 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 2.7M | 913.9K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | ★ 106.71 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $4,213,346,000.00 | N/A |
| Revenue This Year | $2.07 | N/A |
| Revenue Next Year | $1.81 | $699.98 |
| P/E Ratio | $12.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $2.81 |
| 52 Week High | $10.70 | $11.62 |
| Indicator | BLMN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 69.42 | 62.40 |
| Support Level | $6.97 | $6.59 |
| Resistance Level | $8.73 | $11.62 |
| Average True Range (ATR) | 0.45 | 0.95 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 81.54 | 63.29 |
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.